[Muscular dystrophy associated with heart failure].
Ogata
Hitoko
H
Department of Cardiology, KKR Sapporo Medical Center Tonan Hospital.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002304:Cardiac Pacing, Artificial; D016189:Dystrophin / Q000235:genetics; D004452:Echocardiography; D004562:Electrocardiography; D006333:Heart Failure / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D006801:Humans; D009136:Muscular Dystrophies / Q000145:classification / Q000150:complications / Q000235:genetics; D009154:Mutation; D065636:Myotonin-Protein Kinase; D017346:Protein Serine-Threonine Kinases / Q000235:genetics; D018911:Trinucleotide Repeats / Q000235:genetics
D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; C585517:DMPK protein, human; D016189:Dystrophin; D065636:Myotonin-Protein Kinase; D017346:Protein Serine-Threonine Kinases